535 related articles for article (PubMed ID: 11141677)
1. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
3. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
4. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines].
Jackowska T; Wasilewski R
Med Wieku Rozwoj; 2006; 10(3 Pt 1):767-74. PubMed ID: 17317907
[TBL] [Abstract][Full Text] [Related]
6. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, between 1990 and 1996.
Dazzi H; Kaufmann K; Follath F
Ann Oncol; 2001 Jul; 12(7):963-6. PubMed ID: 11521803
[TBL] [Abstract][Full Text] [Related]
10. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
11. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
[TBL] [Abstract][Full Text] [Related]
13. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
14. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
Jones M; O'Gorman P; Kelly C; Mahon N; Fitzgibbon MC
Ann Clin Biochem; 2017 Jan; 54(1):149-157. PubMed ID: 27170025
[TBL] [Abstract][Full Text] [Related]
15. [Cardiotoxicity of anthracycline].
Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapeutics-induced heart failure].
Paulides M; Wojnowski L
Med Klin (Munich); 2007 Jul; 102(7):574-8. PubMed ID: 17634876
[TBL] [Abstract][Full Text] [Related]
17. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.
Krischer JP; Epstein S; Cuthbertson DD; Goorin AM; Epstein ML; Lipshultz SE
J Clin Oncol; 1997 Apr; 15(4):1544-52. PubMed ID: 9193351
[TBL] [Abstract][Full Text] [Related]
18. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
20. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
